Ruediger Hehlmann

Personal Home Page

http://www.iacrlrd.org/.Ruediger Hehlmann

Articles in Scholarly Journals [Incomplete List]

  1. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis
    Cancer, vol. 109, no. 8, pp. 1543–1549, 2007
  2. Zinc protoporphyrin, a useful parameter to address hyperferritinemia
    Annals of Hematology, vol. 86, no. 5, pp. 363–368, 2007
  3. Chronic myeloid leukaemia
    The Lancet, vol. 370, no. 9584, pp. 342–350, 2007
  4. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma
    Leukemia, vol. 21, no. 6, Article ID 2404662, 5 pages, 2007
  5. Systemic mastocytosis simulating osseous metastatic disease
    British Journal of Haematology, vol. 136, no. 1, pp. 1–1, 2007
  6. The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome
    European Journal of Haematology, vol. 79, no. 1, pp. 8–16, 2007
  7. DNA Microarray-Based Detection and Identification of Fungal Pathogens in Clinical Samples from Neutropenic Patients
    Journal of Clinical Microbiology, vol. 45, no. 11, pp. 3743–3753, 2007
  8. Intestinal-type adenocarcinoma situated in the nasopharynx
    Cytopathology, vol. 18, no. 1, pp. 59–63, 2007
  9. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia
    Blood, vol. 109, no. 11, pp. 4635–4640, 2007
  10. Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability
    British Journal of Haematology, vol. 138, no. 3, pp. 369–373, 2007
  11. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia
    Blood, vol. 109, no. 11, pp. 4686–4692, 2007
  12. The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia
    Clinical Chemistry and Laboratory Medicine, vol. 45, no. 10, pp. 1313–1318, 2007
  13. Reliable Identification of Small Cell Lung Cancer in Cytological Specimens by Immunocytology
    Onkologie, vol. 30, no. 6, pp. 311–315, 2007
  14. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor   gene
    Haematologica, vol. 92, no. 2, pp. 163–169, 2007
  15. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
    Haematologica, vol. 92, no. 6, pp. 834–837, 2007
  16. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR
    Haematologica, vol. 92, no. 7, pp. 970–973, 2007
  17. Leukocytoclastic Vasculitis and Acute Renal Failure after Influenza Vaccination in an Elderly Patient with Myelodysplastic Syndrome
    Onkologie, vol. 29, no. 10, pp. 470–472, 2006
  18. Klinische Forschung im „European LeukemiaNet”
    DMW - Deutsche Medizinische Wochenschrift, vol. 131, no. 43, pp. 2423–2426, 2006
  19. Diagnosis and Therapy of Polycythemia Vera
    Seminars in Thrombosis and Hemostasis, vol. 32, no. 3, pp. 267–275, 2006
  20. Cytogenetic response to prior treatment with interferon-a is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia
    Leukemia, vol. 20, no. 3, Article ID 2404100, 7 pages, 2006
  21. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis
    Leukemia, vol. 20, no. 6, Article ID 2404227, 6 pages, 2006
  22. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
    Leukemia, vol. 20, no. 8, Article ID 2404270, 7 pages, 2006
  23. Chronische myeloische Leukämie mit Management-Empfehlungen des European LeukemiaNet
    Der Onkologe, vol. 12, no. 10, pp. 1012–1021, 2006
  24. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and aCDK5RAP2-PDGFRA fusion gene
    Genes, Chromosomes and Cancer, vol. 45, no. 10, pp. 950–956, 2006
  25. Klinische Forschung im Kompetenznetz „Akute und chronische Leukämien“
    Medizinische Klinik, vol. 101, no. 5, pp. 414–420, 2006
  26. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center
    Cancer, vol. 103, no. 8, pp. 1659–1669, 2005
  27. Chronic myeloid leukemia: a model for oncology
    Annals of Hematology, vol. 84, no. 8, pp. 487–497, 2005
  28. Treatment concepts of acute promyelocytic leukemia
    Critical Reviews in Oncology/Hematology, vol. 56, no. 2, pp. 261–274, 2005
  29. BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)
    Investigational New Drugs, vol. 23, no. 4, pp. 363–368, 2005
  30. Induction of centrosome and chromosome aberrations by imatinib in vitro
    Leukemia, vol. 19, no. 9, Article ID 2403861, 5 pages, 2005
  31. The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1
    Leukemia, vol. 19, no. 6, Article ID 2403712, 4 pages, 2005
  32. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies
    Leukemia, vol. 19, no. 6, Article ID 2403756, 5 pages, 2005
  33. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability
    Leukemia, vol. 19, no. 7, Article ID 2403779, 5 pages, 2005
  34. Peritoneal haematopoiesis in acute panmyelosis with myelofibrosis
    British Journal of Haematology, vol. 130, no. 1, pp. 1–1, 2005
  35. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study
    Anti-Cancer Drugs, vol. 16, no. 1, pp. 39–45, 2005
  36. Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial
    Anti-Cancer Drugs, vol. 16, no. 4, pp. 435–440, 2005
  37. Soluble transferrin receptor and zinc protoporphyrin - competitors or efficient partners?
    European Journal of Haematology, vol. 75, no. 4, pp. 309–317, 2005
  38. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase
    European Journal of Haematology, vol. 75, no. 6, pp. 518–521, 2005
  39. Comprehensive Analysis of Human Endogenous Retrovirus Transcriptional Activity in Human Tissues with a Retrovirus-Specific Microarray
    Journal of Virology, vol. 79, no. 1, pp. 341–352, 2005
  40. Human Endogenous Retrovirus Expression Profiles in Samples from Brains of Patients with Schizophrenia and Bipolar Disorders
    Journal of Virology, vol. 79, no. 17, pp. 10890–10901, 2005
  41. IgA nephropathy and hodgkins disease: A rare coincidence. Case report and literature review
    American Journal of Kidney Diseases, vol. 45, no. 1, pp. e16–e19, 2005
  42. Phase I Trial of Capecitabine and Weekly Irinotecan in Combination With Radiotherapy for Neoadjuvant Therapy of Rectal Cancer
    Journal of Clinical Oncology, vol. 23, no. 7, pp. 1350–1357, 2005
  43. Impact of Chemoradiotherapy-Induced Anemia on Survival in Uniformly Staged Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus
    Onkologie, vol. 27, no. 5, pp. 462–466, 2004
  44. Fatal cerebral involvement in systemic aspergillosis: a rare complication of steroid-treated autoimmune bicytopenia
    European Journal of Haematology, vol. 72, no. 5, pp. 375–376, 2004
  45. Detection of Aspergillus DNA by a nested PCR assay is superior to blood culture in an experimental murine model of invasive aspergillosis
    Journal of Medical Microbiology, vol. 53, no. 8, pp. 803–806, 2004
  46. Standardization of Preanalytical Factors for Minimal Residual Disease Analysis in Chronic Myelogenous Leukemia
    Acta Haematologica, vol. 112, no. 1-2, pp. 30–33, 2004
  47. Prospective clinical evaluation of a LightCyclerTM-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients
    British Journal of Haematology, vol. 125, no. 2, pp. 196–202, 2004
  48. Current Molecular Diagnostic Approaches to Systemic Infections with Aspergillus Species in Patients with Hematological Malignancies
    Leukemia & Lymphoma, vol. 45, no. 3, pp. 463–468, 2004
  49. Therapie der chronischen myeloischen Leukämie 2004
    DMW - Deutsche Medizinische Wochenschrift, vol. 129, no. 40, pp. 2122–2127, 2004
  50. Das Kompetenznetzwerk „Akute und chronische Leukämien”
    DMW - Deutsche Medizinische Wochenschrift, vol. 129, no. 49, pp. 2660–2665, 2004
  51. Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial
    British Journal of Cancer, Article ID 6602025, 2004
  52. Imatinib?Neuartige, molekulare Therapiem?glichkeit bei chronischer myeloischer Leuk?mie
    Der Internist, vol. 45, no. 1, pp. 102–103, 2004
  53. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha
    Leukemia, vol. 19, no. 3, Article ID 2403607, 3 pages, 2004
  54. The German competence network ‘Acute and chronic leukemias’
    Leukemia, vol. 18, no. 4, Article ID 2403317, 4 pages, 2004
  55. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia
    Leukemia, vol. 18, no. 9, Article ID 2403451, 7 pages, 2004
  56. Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer
    British Journal of Cancer, vol. 90, no. 10, Article ID 6601786, 4 pages, 2004
  57. Klinische Forschung im Kompetenznetz ?Akute und chronische Leuk?mien?
    Der Internist, vol. 45, no. 4, pp. 384–392, 2004
  58. Management of infections in critically ill neutropenic cancer patients
    Journal of Critical Care, vol. 19, no. 3, pp. 165–173, 2004
  59. Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient
    Cancer Chemotherapy and Pharmacology, vol. 53, no. 3, pp. 276–278, 2004
  60. Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection?case report and review of the literature
    Annals of Hematology, vol. 83, no. 3, pp. 189–194, 2004
  61. Imatinib and beyond?the new CML study IV
    Annals of Hematology, vol. 83, no. 4, pp. 258–264, 2004
  62. Chronische myeloproliferative Erkrankungen
    Der Internist, vol. 44, no. 8, pp. 1011–1030, 2003
  63. Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy
    Seminars in Hematology, vol. 40, no. 1, pp. 4–12, 2003
  64. Multilobated nuclei in Waldenstrom' macroglobulinaemia
    European Journal of Haematology, vol. 71, no. 4, pp. 307–310, 2003
  65. Assessment of retroviral activity using a universal retrovirus chip
    Journal of Virological Methods, vol. 112, no. 1-2, pp. 79–91, 2003
  66. Randomized comparison of interferon a and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon a and hydroxyurea
    Leukemia, vol. 17, no. 8, Article ID 2403006, 8 pages, 2003
  67. Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission
    Leukemia, vol. 17, no. 9, Article ID 2403033, 7 pages, 2003
  68. Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy
    Cancer Genetics and Cytogenetics, vol. 143, no. 1, pp. 59–72, 2003
  69. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate
    Leukemia, vol. 17, no. 2, Article ID 2402813, 2 pages, 2003
  70. Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy
    Seminars in Hematology, vol. 40, no. 1, pp. 4–12, 2003
  71. Current CML therapy: progress and dilemma
    Leukemia, vol. 17, no. 6, Article ID 2402951, 2 pages, 2003
  72. Pseudomembranous tracheobronchial aspergillosis: a rare manifestation of invasive aspergillosis in a non-neutropenic patient with Hodgkin's disease. Fallbericht. Pseudomembranose tracheobronchiale Aspergillose: Seltene Manifestation einer Aspergillus-Infektion bei einer nicht-neutropenischen Patientin mit Morbus Hodgkin
    Mycoses, vol. 46, no. 1-2, pp. 51–55, 2003
  73. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon a/ara-C
    Leukemia, vol. 17, no. 12, Article ID 2403157, 8 pages, 2003
  74. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon a
    Leukemia, vol. 17, no. 9, Article ID 2403042, 6 pages, 2003
  75. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome
    Leukemia, vol. 17, no. 12, Article ID 2403161, 2 pages, 2003
  76. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial
    Leukemia, vol. 17, no. 12, Article ID 2403172, 9 pages, 2003
  77. Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia
    Blood, vol. 101, no. 1, pp. 375–375, 2003
  78. Development of a LightCycler PCR Assay for Detection and Quantification of Aspergillus fumigatus DNA in Clinical Samples from Neutropenic Patients
    Journal of Clinical Microbiology, vol. 41, no. 5, pp. 1811–1818, 2003
  79. Treatment of a Patient with Advanced Esophageal Cancer with a Combination of Mitomycin C and Capecitabine: Activation of the Thymidine Phosphorylase as Active Principle?
    Onkologie, vol. 26, no. 2, pp. 161–164, 2003
  80. High-Dose 5-Fluorouracil / Folinic Acid in Combination with Three-Weekly Mitomycin C in the Treatment of Advanced Gastric Cancer. A Phase II Study
    Onkologie, vol. 25, no. 3, pp. 255–260, 2002
  81. Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea
    Proceedings of the National Academy of Sciences, vol. 99, no. 10, pp. 6778–6783, 2002
  82. Interferon-alpha , but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia
    Blood, vol. 101, no. 1, pp. 259–264, 2002
  83. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer???a phase II study
    Anti-Cancer Drugs, vol. 13, no. 10, pp. 999–1004, 2002
  84. Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients
    British Journal of Haematology, vol. 116, no. 4, pp. 803–811, 2002
  85. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon a
    Leukemia, vol. 16, no. 9, Article ID 2402680, 4 pages, 2002
  86. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
    Leukemia, vol. 16, no. 11, pp. 2190–2196, 2002
  87. Alveolar rhabdomyosarcoma with bone marrow infiltration mimicking haematological neoplasia
    British Journal of Haematology, vol. 119, no. 3, pp. 583–583, 2002
  88. Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)
    Leukemia, vol. 16, no. 7, pp. 1220–1228, 2002
  89. Echokardiographischer Nachweis von Trikuspidalklappen-Vegetationen und rechtskardialen Raumforderungen bei einem Patienten mit akuter myeloischer Leukämie
    Ultraschall in der Medizin, vol. 23, no. 5, pp. 341–344, 2002
  90. Diagnostik und Therapie der chronischen myeloischen Leukämie
    Der Onkologe, vol. 8, no. 7, pp. 693–707, 2002
  91. Aktuelle Therapiekonzepte bei chronischer myeloischer Leukämie
    Der Internist, vol. 43, no. 10, pp. 1228–1244, 2002
  92. Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy
    Annals of Hematology, vol. 81, no. 8, pp. 467–469, 2002
  93. Predominantly BCR-ABL negative myeloid precursors in interferon-α treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization
    Annals of Hematology, vol. 80, no. 1, pp. 9–16, 2001
  94. Functional Activity of HERV-K-T47D-Related Long Terminal Repeats
    Virology, vol. 283, no. 2, pp. 262–272, 2001
  95. Therapie der Polycythaemia vera
    DMW - Deutsche Medizinische Wochenschrift, vol. 126, no. 14, pp. 415–415, 2001
  96. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia
    Leukemia, vol. 15, no. 1, pp. 62–68, 2001
  97. bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements
    British Journal of Haematology, vol. 113, no. 2, pp. 383–390, 2001
  98. Current therapeutic concept of acute promyelocytic leukaemia
    DMW - Deutsche Medizinische Wochenschrift, vol. 126, no. 39, pp. 1073–1079, 2001
  99. Detection of [ITAL]Aspergillus[/ITAL] Species in Blood and Bronchoalveolar Lavage Samples from Immunocompromised Patients by Means of 2-Step Polymerase Chain Reaction: Clinical Results
    Clinical Infectious Diseases, vol. 33, no. 4, pp. 428–435, 2001
  100. Polyzythämia vera - Aktueller Stand der Therapie
    DMW - Deutsche Medizinische Wochenschrift, vol. 126, no. 19, pp. 575–575, 2001
  101. Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy
    Proceedings of the National Academy of Sciences, vol. 98, no. 20, pp. 11283–11288, 2001
  102. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha
    Blood, vol. 97, no. 11, pp. 3648–3650, 2001
  103. Die Bedeutung der Vernetzung für die klinische Forschung der Zukunft
    Onkologie, vol. 24, no. 4, pp. 380–384, 2001
  104. Phase II Study of a Weekly 24-Hour Infusion with 5-Fluorouracil and Simultaneous Sodium – Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer
    Onkologie, vol. 24, no. 5, pp. 457–462, 2001
  105. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia
    Blood, vol. 98, no. 9, pp. 2879–2880, 2001
  106. AraC-based pharmacotherapy of chronic myeloid leukaemia
    Expert Opinion on Pharmacotherapy, vol. 2, no. 7, pp. 1129–1135, 2001
  107. Selektive Hemmung von Tyrosinkinasen als neues therapeutisches Prinzip in der Onkologie
    Onkologie, vol. 24, no. Suppl. 5, pp. 65–71, 2001
  108. Chronic myeloid leukemia and interferon-alpha : a study of complete cytogenetic responders
    Blood, vol. 98, no. 10, pp. 3074–3081, 2001
  109. Systemic Infections with Aspergillus Species in Patients with Hematological Malignancies: Current Serological and Molecular Diagnostic Approaches
    Onkologie, vol. 24, no. 6, pp. 531–536, 2001
  110. Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A
    Blood, vol. 98, no. 13, pp. 3874–3875, 2001
  111. Combination of Bolus 5-Fluorouracil, Folinic Acid and Mitomycin C in Advanced Gastric Cancer: Results of a Phase II Trial
    Onkologie, vol. 23, no. 5, pp. 444–447, 2000
  112. Systemic Infections with Candida sp. and Aspergillus sp. in Immunocompromised Patients with Hematological Malignancies: Current Serological and Molecular Diagnostic Methods
    Chemotherapy, vol. 46, no. 3, pp. 219–228, 2000
  113. Rapid Identification of All Known Retroviral Reverse Transcriptase Sequences with a Novel Versatile Detection Assay
    AIDS Research and Human Retroviruses, vol. 16, no. 8, pp. 721–729, 2000
  114. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials
    British Journal of Haematology, vol. 110, no. 3, pp. 573–576, 2000
  115. HERV-IP-T47D, a Novel Type C-Related Human Endogenous Retroviral Sequence Derived from T47D Particles
    AIDS Research and Human Retroviruses, vol. 16, no. 5, pp. 471–480, 2000
  116. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia
    Leukemia, vol. 14, no. 8, pp. 1362–1370, 2000
  117. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes
    Leukemia, vol. 14, no. 11, pp. 2006–2010, 2000
  118. Polyzythämia vera - Aktueller Stand der Therapie -
    DMW - Deutsche Medizinische Wochenschrift, vol. 125, no. 41, pp. 1243–1247, 2000
  119. Detection and quantification of residual disease in chronic myelogenous leukemia
    Leukemia, vol. 14, no. 6, pp. 998–1005, 2000
  120. Interferon α in the treatment of polycythemia vera
    Annals of Hematology, vol. 79, no. 3, pp. 103–109, 2000
  121. HERV-K-T47D-Related Long Terminal Repeats Mediate Polyadenylation of Cellular Transcripts
    Genomics, vol. 66, no. 1, pp. 98–103, 2000
  122. Current trends in the management of chronic myelogenous leukemia
    Annals of Hematology, vol. 79, no. 7, pp. 345–354, 2000
  123. CD14+ peripheral blood mononuclear cells from chronic myeloid leukemia and normal donors are inhibitory to short- and long-term cultured colony-forming cells
    Leukemia Research, vol. 24, no. 3, pp. 217–231, 2000
  124. Aneuploidy Precedes and Segregates with Chemical Carcinogenesis
    Cancer Genetics and Cytogenetics, vol. 119, no. 2, pp. 83–93, 2000
  125. Comparative research in leukemia and related diseases. An introduction to a scientific approach
    Leukemia, vol. 13, Article ID 2401289, 1999